Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds Casesgenetics-dysmorphology-and-metabolism

Paeds Cases · genetics-dysmorphology-and-metabolism

Normal microarray and developmental delay — genomic testing strategy OSCE

OSCE on counselling a family through a normal chromosomal microarray, justifying escalation to whole-exome or whole-genome sequencing, consent for the variant of uncertain significance and secondary findings, and the plan for re-analysis.

osce communication and shared decision-making
On this page & tools

Target exams

MRCPCH ClinicalRACP DCE

Target exams

MRCPCH ClinicalRACP DCE
Prompt
The parents of a four-year-old boy with global developmental delay attend clinic after a normal chromosomal microarray. They are anxious that 'there is nothing wrong genetically' and confused about why more testing is being suggested. Counsel them on what the normal result means, the next test, and the consent points.

Objectives

  1. Explain what a normal chromosomal microarray does and does not exclude. [1]
  2. Justify escalation to whole-exome or whole-genome sequencing with an honest yield. [2]
  3. Conduct pre-test counselling on the variant of uncertain significance and the secondary-findings opt-out. [6] [10]
  4. Build a plan for re-analysis and a definite review. [2]

Candidate brief

Twelve-minute station. The parents and their four-year-old son are present. The referral is global developmental delay. The microarray is normal. The parents have interpreted the normal result as reassurance that no genetic cause exists, and they are wary of more testing. [1]

Expected actions

  • Acknowledge the parents' relief and gently correct the misinterpretation: a normal microarray excludes only the common copy-number causes. [1]
  • Explain that microarray does not detect single-base spelling changes in genes or repeat expansions, so a genetic cause remains possible. [1]
  • Introduce whole-exome or whole-genome sequencing as the next test, quoting an honest yield and the benefit of a trio approach. [2]
  • Counsel on the variant of uncertain significance — a real finding whose meaning is not yet known — and on the secondary-findings opt-out. [6] [10]
  • Set a definite review and explain that a negative result can be re-analysed as knowledge grows. [2]

Parent actor prompts

  • "The doctor said the chromosome test was normal, so there is nothing wrong with him genetically. Why are you sending more tests?" [1]
  • "What if this new test finds something else — something in me? I do not want to know that." [10]

Model communication lines

"The normal microarray is good news because it rules out the common large chromosome changes that cause developmental delay. But it is like checking the chapter headings of a book — it does not read the individual words. A spelling mistake in a single gene, or a different kind of change called a repeat expansion, would not show up on that test, and those are common causes of developmental delay too. So the normal result does not mean there is no genetic cause; it means we have not found it yet. The next test, exome or genome sequencing, reads the genes letter by letter, and it finds an answer in about a third of children in this situation. I would test you both as well, because comparing you helps us interpret the result. There are two things I want you to know before we go ahead. First, we may find a change whose meaning we are not yet sure of — we would not treat that as a diagnosis, and we would discuss it carefully. Second, the test can pick up unrelated findings, for example a gene linked to cancer risk in adults — you can choose whether to receive those, and there is no wrong answer. Whatever the result, I will book a time to go through it with you, and if it is negative we can re-analyse it in the future as our knowledge grows." [1] [2] [6] [10]

Marking

Pass: correctly explains what a normal microarray excludes and does not exclude; justifies escalation to exome or genome sequencing with an honest yield and the trio concept; counsels on the variant of uncertain significance and the secondary-findings opt-out without overwhelming the family; sets a definite review and offers re-analysis. [1] [2] [10] Fail: reassurance that a normal microarray excludes a genetic cause; offering sequencing without counselling on the variant of uncertain significance or secondary findings; or an open-ended wait with no review plan. [6]

References

  1. [1]Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. American Journal of Human Genetics, 2010.PMID 20466091
  2. [2]Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021.PMID 34211152
  3. [6]Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 2015.PMID 25741868
  4. [10]Miller DT, Lee K, Chung WK, Gordon AS, Hagstrom SA, Klein TE ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2023.PMID 37347242